Evidence strength for the context described on this page.
PEPTIDE ATLAS / METABOLIC & FAT LOSS / SEMAGLUTIDE
EvidenceHigh for approved indicationi
RegulatoryFDA-approvedi
Semaglutide

A GLP-1 receptor agonist with strong outcome data for defined metabolic indications.
HOW TO USE THIS PAGE
Read the profile in the order that protects the decision.
- 01Verify what it is
Confirm the exact molecule, route, regulatory lane and actual human evidence.
- 02Read the evidence limits
Unsupported claims, contraindications and uncertainty come before any protocol.
- 03Build the monitoring plan
Define the target, baseline checks, reassessment point and stop rules with a qualified clinician.
The five facts to know first.
Status is product-, formulation- and indication-specific.
Public education does not establish a personal treatment plan.
Plus 2 research searches. A search link is not a cited study or proof of a claim.
Peptide hormones, growth factors and related substances may be prohibited.
Check Global DRO ↗Where present, the date above records an editorial content review, not medical approval or a live check of every claim. Follow the official product label and regulator links for current status. This page does not establish availability through Modern Bio.
How we describe evidence →OVERVIEW
What Semaglutide is.
A long-acting peptide analog of glucagon-like peptide-1. Different branded products have different indications, formulations and dose schedules; they are not interchangeable simply because the active ingredient is related.
Activates GLP-1 receptors, increasing glucose-dependent insulin signaling, reducing glucagon when glucose is elevated, slowing gastric emptying and changing appetite signaling.
Semaglutide products differ by indication and formulation. Wegovy includes tablets and injections; its MASH indication uses accelerated approval and still requires confirmation of clinical benefit. Do not generalize one formulation’s indication or risk profile to another. This summary is not the full label.
Read the current Wegovy label ↗This checks the stated regulatory point only, not every clinical claim in the profile.
EFFECTS & EVIDENCE
What the evidence supports—and what it does not.
- Substantial average weight reduction in eligible adults when paired with long-term lifestyle care
- Improved glycemic control in type 2 diabetes
- Cardiovascular risk reduction for specific labeled populations
- A universal weight-loss drug for anyone wanting to be leaner
- A substitute for resistance training, adequate protein or clinical follow-up
- That compounded or salt-form products are equivalent to FDA-approved brands
Evidence grade: High for approved indication. For an approved drug, “high” refers only to its labeled indication—not every off-label or wellness claim.
CLINICAL CONTEXT
The decision is individual.
Approval applies to a specific product and indication. A licensed clinician must evaluate whether the exact treatment fits your history, current medications and goals.
Identify the outcome, formulation and population actually studied.
Review benefits, uncertainty, contraindications and better-studied alternatives.
A treatment decision needs a responsible clinician, monitoring and a review date.
This public guide does not provide a dosing, injection or self-treatment protocol. Bring the source links and the exact product into a licensed clinical consultation.
MONITORING
What should be tracked.
- Weight trajectory, waist and functional goals
- Glucose and diabetes-medication adjustment when relevant
- Hydration, severe GI symptoms, gallbladder symptoms and relevant vision changes
- Medication review and advance discussion of planned anesthesia or deep sedation
SAFETY
Risks, red flags and reasons to avoid it.
- Nausea, vomiting, diarrhea, constipation and abdominal pain; gastrointestinal reactions can be severe
- Gallbladder disease, pancreatitis warning and dehydration-related kidney injury
- Hypoglycemia with insulin or insulin secretagogues; retinopathy complications in some patients with type 2 diabetes
- Potential increased risk of rare NAION; sudden, painless one-eye vision changes require immediate clinician contact
- Boxed thyroid C-cell tumor warning; human relevance uncertain, with MTC/MEN2 contraindications
- Serious hypersensitivity and pulmonary aspiration during general anesthesia or deep sedation
- Personal or family history of medullary thyroid carcinoma or MEN2
- Prior serious hypersensitivity to semaglutide or product ingredients
- Severe gastroparesis: Wegovy is not recommended
- Weight-loss use during pregnancy; pregnancy planning requires indication-specific prescriber guidance
- Using multiple GLP-1 drugs together or unverified products
CLINICIAN VISIT CHECKLIST
Six questions worth bringing with you.
Molecule or analog, salt, concentration, route, manufacturer or compounder, lot and beyond-use date.
Name the diagnosis or target, how it will be measured and the realistic time to reassess.
Ask how it compares with FDA-approved, lower-risk or better-studied alternatives.
Label, human trial, specialty guideline or clinic convention—and whether that route and formulation match.
Baseline checks, follow-up measures, interactions, pregnancy considerations and symptoms that mean stop.
Pharmacy license, prescription, identity/potency testing, sterility controls and who handles a product complaint.
Do not improvise reconstitution or convert “units” without the exact concentration. Mixing, storage and beyond-use instructions are product-specific; confirm them with the dispensing pharmacy.
SOURCES & RESEARCH LINKS
Read the record yourself.
We prioritize official prescribing information, FDA regulatory material, registered trials and indexed biomedical literature. Vendor and community dosing protocols are excluded from this public source list. These are supporting reading links, not a completed claim-by-claim citation map. Search links can lead to changing results; their presence does not establish that a particular study supports this profile.
PRODUCTS & TREATMENT ACCESS
Use a verified prescription pathway.
Prescription-only FDA-approved products. FDA states compounded drugs are not FDA-approved and has warned about dosing errors, salt forms and misleading equivalence claims.
The molecule has high-quality evidence; product provenance still matters. A vial marketed as semaglutide is not automatically equivalent to a branded, approved product.
Learn now. Verify care separately.
This guide is not a booking or prescribing service. Clinical appointments and prescription decisions are handled separately from this educational Atlas.
Review care readiness and standards →NEXT STEP
Return to metabolic & fat loss peptides.
Explore the category →YOUR NEXT STEP
Ready for a clinician-led plan?
Clinical review determines the appropriate next step. No treatment is guaranteed.
THE CARE PATH
We order your labs
A licensed clinician reviews results and recommends a plan
Rx sent directly to you when appropriate
Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.
Start your lab reviewExplore free educational tools